Enhanced Features to Guide Decisions for Drug Optimisation

Optibrium launched StarDrop 4.3. The intuitive software offers advantages over traditional predictive modeling platforms as it specifically helps users to identify chemistries with a high chance of success and focus expensive in-house resources. Used by pharmaceutical and biotech companies and research establishments globally, StarDrop 4.3 guides compound selection and design decisions in all stages of drug discovery. StarDrop 4.3 is the first major update to StarDrop from Optibrium, helping scientists to select high quality drug candidates with confidence, improving efficiency and productivity. StarDrop 4.3 helps drug discovery scientists to guide their decisions while designing and prioritising molecules with the aim of achieving an optimal balance of properties. By combining predicted (in silico) properties for molecules with measured in vitro and in vivo data, this integrated desktop tool enables scientists to rapidly identify and design high quality molecules to meet their project’s objectives.

The revolutionary software takes into account the potential errors to provide scientists with a rigorous analysis on which to make rational decisions. StarDrop 4.3 is groundbreaking software that enables confident decisions to be made despite all of the uncertainty. Additional new enhancements to StarDrop 4.3 include the ‘Molecule View’ feature that goes beyond traditional ‘table’ views of data sets and enables users to drag and drop properties to customise layout for viewing and printing and scroll through their compounds viewing all properties together. New features unique to StarDrop 4.3 include more flexible data set views. Direct printing support enables users to print individual molecules with data from both table and molecule views. In addition, the range of powerful Gaussian Process methods in StarDrop’s Auto-Modeller has been extended to provide new techniques for building classification models. StarDrop 4.3 offers unique benefits across the spectrum of drug discovery, helping clients make businesscritical choices. Benefits include better molecule design, faster
selection and optimisation of molecules, reduced late-stage bottlenecks, strengthened pipelines and reductions in cost. The software provides a comprehensive range of features to support design and prioritisation of high quality compounds including: probabilistic scoring; chemical space and glowing molecule visualisation; ADME QSAR models; P450 metabolism models and automatic model building.